Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
1995-04-05
2001-06-05
Leary, Louise (Department: 1211)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C435S002000, C436S066000, C436S063000, C436S016000, C436S015000, C436S074000
Reexamination Certificate
active
06242417
ABSTRACT:
FIELD OF INVENTION
The present invention relates to novel hemoglobin-containing compositions stabilized to inhibit aggregate formation therein.
BACKGROUND OF THE INVENTION
The oxygen carrying portion of red blood cells is the protein hemoglobin. Hemoglobin is a tetrameric protein molecule composed of two identical alpha globin subunits (&agr;
1
, &agr;
2
), two identical beta globin subunits (&bgr;
1
, &bgr;
2
) and four heme molecules. A heme molecule is incorporated into each of the alpha and beta globins to give alpha and beta subunits. Heme is a large macrocyclic organic molecule containing an iron atom; each heme can combine reversibly with one ligand molecule such as oxygen. In a hemoglobin tetramer, each alpha subunit is associated with a beta subunit to form two stable alpha/beta dimers, which in turn associate to form the tetramer. The subunits are noncovalently associated through Van der Waals forces, hydrogen bonds and salt bridges.
Hemoglobin in solution can be used, for example, as a blood substitute, as a therapeutic for enhancing hematopoiesis, as a means of delivering oxygen or enhancing oxygen delivery to tissues, for hemoaugmentation, for the binding or delivery of nitric oxide or other non-oxygen ligands, as a drug delivery vehicle, as a cell culture additive, as a reference standard, and as an imaging agent. However, storage of hemoglobin solutions can be problematic Proteins in solution can form aggregates upon long term storage, changes in temperature during storage, or mechanical agitation (Cleland, et al.,
Crit. Rev. Ther. Drug Carrier Systems
10: 307-377 (1993). To address these problems, many unique formulations have been developed for the stabilization of different proteins in solution. For example, both naturally derived and recombinantly produced proteins have been formulated in solutions containing disaccharides and amino acids (factor VII or factor IX solutions described in PCT Publication WO 91/10439 (1991) to Octapharma), human serum albumin (interleukin-2 solutions described in U.S. Pat. No. 4,645,830 to Yasushi et al.), and glycine, mannitol and non-ionic surfactants (human growth hormone solutions described in U.S. Pat. No. 5,096,885 to Pearlman et al.). Although some general guidance is available for the determination of suitable components for formulations for protein solutions, because of the unique nature of individual proteins, no single formulation is suitable for all different proteins. Indeed, Cleland et al. (1993) state that the creation of a formulation that minimizes protein degradation is difficult because there are many factors that interact to determine protein degradation in a formulation. They go on to state that “protein degradation . . . cannot be predicted a priori and must be determined for each protein”.
To extend the storage stability of hemoglobin solutions by limiting autooxidation, hemoglobin has been formulated with reducing agents such as cysteine or dithionite, mannitol, glucose and/or alpha tocopherol (Shorr et al., PCT Publication WO 94/01452 (1994)), in saline solutions or lactated Ringer's solutions that have been modified by the addition of, for example ascorbate, ATP, glutathione and adenosine (Feola et al., PCT Publication WO 91/09615 (1991); Nelson et al, PCT Publication WO 92/03153), under deoxygenated conditions with no exogenous reductants (Kandler and Spicussa, PCT Publication WO 92/02239 (1992)), or in the presence of reducing enzyme systems (Sehgal et al., U.S. Pat. No. 5,194,590). These hemoglobin formulations have been designed to minimize autooxidation of the protein molecule, but none have been designed that specifically reduce the aggregation of the hemoglobin molecules during storage.
Nonetheless, the aggregation of hemoglobin molecules during storage poses significant problems. Moore et al.,
Art. Org.
16: 513-518 (1992) caution that hemoglobin should not be stored in the frozen state due to the formation of aggregates or precipitates. Moreover, the formation of aggregates in hemoglobin solutions agitated at room temperature has been observed in numerous formulations (Pristoupil and Marik,
Biomat. Art. Cells, Art. Org.,
18: 183-188, 1990; Adachi and Asakura,
J. Biol. Chem.,
256: 1824-1830, 1981; Adachi and Asakura,
Biochem.,
13: 4976-4982, 1974). This aggregation of the hemoglobin protein molecule typically does not occur as a result of autooxidation of the hemoglobin heme iron, but rather by interaction of the hemoglobin molecules (Adachi et al.,
Fed. Proc.
35: 1392 (1976). Aggregates in hemoglobin solutions can increase immunogenicity, reduce functionality and reduce the activity of the protein solution (Cleland et al., supra; Feola et al.,
Biomat. Art. Cells Art. Org.
16: 217-226 (1988).
Accordingly, there is a need for hemoglobin compositions stabilized against the formation of aggregates. The present invention satisfies this need and provides related advantages as well.
SUMMARY OF THE INVENTION
The present invention relates to compositions containing hemoglobin wherein the hemoglobin is stabilized with a surfactant to inhibit the formation of aggregates. In one embodiment, compositions of the invention contain about 0.001% to about 90% by weight to volume hemoglobin and 0.01 to 1% (weight to volume) of a surfactant and can also include 0-200 mM of one or more buffers, 0-200 mM of one or more alcohols or polyalcohols, 0-300 mM of one or more salts and 0-5 mM of one or more reducing agents. In a further embodiment, the compositions can contain 0.1-50% by weight to volume of hemoglobin, 0-50 mM of one or more buffers, 0-200 mM of one or more salts, 0.02%-0.5% (weight to volume) of one or more surfactants, 0-5 mM of one or more reducing agents and is at pH of about 6.8 to 7.8. Another aspect of the invention are compositions containing about 1 to about 20% by weight to volume of hemoglobin, 5-15 mM sodium phosphate, 100-185 mM sodium chloride, 0.02%-0.08% (weight to volume) polysorbate 80, 1-4 mM of ascorbate and is at pH of about 6.8 to 7.6. A still further embodiment of the present invention is a method for stabilizing compositions containing hemoglobin to inhibit the formation of aggregates comprising adding to the composition a stabilizing amount of a surfactant.
Other features and advantages of the invention will be apparent from the following description of the invention and from the claims.
REFERENCES:
patent: 3847545 (1974-11-01), Shanbrom et al.
patent: 3997470 (1976-12-01), Monte et al.
patent: 4001200 (1977-01-01), Bonsen et al.
patent: 4001401 (1977-01-01), Bonsen et al.
patent: 4053590 (1977-10-01), Bonsen et al.
patent: 4061736 (1977-12-01), Morris et al.
patent: 4301144 (1981-11-01), Iwashita et al.
patent: 4321259 (1982-03-01), Nicolau et al.
patent: 4336248 (1982-06-01), Bonhard
patent: 4377512 (1983-03-01), Ajisaka et al.
patent: 4401652 (1983-08-01), Simmonds
patent: 4412989 (1983-11-01), Iwashita et al.
patent: 4439357 (1984-03-01), Bonhard et al.
patent: 4473494 (1984-09-01), Tye
patent: 4473496 (1984-09-01), Scannon
patent: 4473563 (1984-09-01), Nicolau et al.
patent: 4526715 (1985-07-01), Kothe
patent: 4529719 (1985-07-01), Tye
patent: 4584130 (1986-04-01), Bucci et al.
patent: 4598064 (1986-07-01), Walder
patent: 4600531 (1986-07-01), Walder
patent: 4626511 (1986-12-01), Artiss et al.
patent: 4645830 (1987-02-01), Yasushi et al.
patent: 4650786 (1987-03-01), Wong
patent: 4670417 (1987-06-01), Iwasaki et al.
patent: 4703008 (1987-10-01), Lin
patent: 4710488 (1987-12-01), Wong
patent: 4777244 (1988-10-01), Bonhard et al.
patent: 4810643 (1989-03-01), Souza
patent: 4826811 (1989-05-01), Sehgal et al.
patent: 4857636 (1989-08-01), Hsia
patent: 4861867 (1989-08-01), Estep
patent: 4868119 (1989-09-01), Clark et al.
patent: 4876188 (1989-10-01), Smith et al.
patent: 4880749 (1989-11-01), Burdick et al.
patent: 4920194 (1990-04-01), Feller et al.
patent: 4965251 (1990-10-01), Stamatoyannopoulos
patent: 5004681 (1991-04-01), Boyse et al.
patent: 5028588 (1991-07-01), Hoffman et al.
patent: 5032396 (1991-07-01), Williams
patent: 5032507 (1991-07-01), Yu et a
Gerber Michael J.
Kerwin Bruce A.
Looker Douglas L.
Brown Theresa A.
Leary Louise
Novelli Marianne F.
Somatogen, Inc.
LandOfFree
Stabilized compositions containing hemoglobin does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Stabilized compositions containing hemoglobin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Stabilized compositions containing hemoglobin will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2482642